Profound Medical (NASDAQ:PROF – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Risk & Volatility
Profound Medical has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
Insider & Institutional Ownership
47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -275.16% | -86.18% | -70.55% |
| Reviva Pharmaceuticals | N/A | -20,501.80% | -187.50% |
Analyst Recommendations
This is a breakdown of current recommendations for Profound Medical and Reviva Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
| Reviva Pharmaceuticals | 1 | 0 | 7 | 0 | 2.75 |
Profound Medical presently has a consensus price target of $12.00, indicating a potential upside of 75.95%. Reviva Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 1,098.61%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Profound Medical.
Valuation and Earnings
This table compares Profound Medical and Reviva Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profound Medical | $10.68 million | 23.17 | -$27.82 million | ($1.34) | -5.09 |
| Reviva Pharmaceuticals | N/A | N/A | -$29.92 million | ($0.46) | -0.60 |
Profound Medical has higher revenue and earnings than Reviva Pharmaceuticals. Profound Medical is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Reviva Pharmaceuticals beats Profound Medical on 8 of the 13 factors compared between the two stocks.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.
